Investing in Oncodesign, a driver of therapeutic innovation

Our organization by Business Unit boosts the quality of our active compounds

To boost the quality of each compound, our company has been organized into Business Units since January 2020. This organization also aims to make the Group’s activities clearer for employees, customers, partners and investors. Each BU has its own objectives and resources.  They will naturally lead to subsidiaries in the coming years depending on their level of maturity.

Stock market information

Since opening
Since yesterday

Financial calendar

2021 Full-Year Revenue
2021 Full-Year Results
Annual General Meeting 2022
2022 Half-Year Revenue
2022 Half-Year Results


Are you a shareholder? You can receive all useful information for your investments directly by e-mail.

Oncodesign Portraits

Message from the Chairman

"Oncodesign has been listed on Euronext Growth Market since April 2014 (ALONC, Paris). Our biggest goal since our creation has been to discover effective therapies to fight cancer and other diseases for which no treatment is currently available. We have built a unique platform of precision medicine dedicated to resistant or refractory diseases (...)"

Lire la suite

Interested in a possible investment?